T cell augments the antitumor activity of tumor-targeting Salmonella. 2011

Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
Department of Microbiology, School of Medicine, China Medical University, Taichung, Taiwan. chlee@mail.cmu.edu.tw

Systemic administration of Salmonella to tumor-bearing mice leads to preferential accumulation within tumor sites and retardation of tumor growth. However, the detailed mechanism of Salmonella-induced antitumor immune response via host T cell remains uncertain. Herein, we used wild-type, CD4(+) T-cell-deficient, and CD8(+) T-cell-deficient mice to study the role of T cell in the antitumor immune responses induced by Salmonella enterica serovar Choleraesuis (Salmonella Choleraesuis). When systemically administered into mice bearing tumors, Salmonella Choleraesuis significantly inhibited tumor growth by 50%. In contrast, in T-cell-deficient mice, there was only 34-42% inhibition of tumor growth. We found that treatment with Salmonella Choleraesuis significantly upregulates interferon-γ in wild-type and CD8(+) T-cell-deficient mice, but not in CD4(+) T-cell-deficient mice. Furthermore, immunohistochemical staining of the tumors revealed more infiltration of macrophages and neutrophils in wild-type mice after Salmonella Choleraesuis treatment compared with those in T-cell-deficient mice. The antitumor therapeutic effect mediated by Salmonella Choleraesuis is associated with an inflammatory immune response at the tumor site and a tumor T helper 1-type immune response. In conclusion, these results suggest that tumor-targeted therapy using Salmonella Choleraesuis, which exerts tumoricidal effects and stimulates T cell activities, represents a potential strategy for the treatment of tumor.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001691 Biological Therapy Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents. Biologic Therapy,Biotherapy,Therapy, Biological,Biologic Therapies,Biological Therapies,Biotherapies,Therapies, Biologic,Therapies, Biological,Therapy, Biologic
D012480 Salmonella Infections Infections with bacteria of the genus SALMONELLA. Salmonellosis,Infections, Salmonella,Infection, Salmonella,Salmonella Infection,Salmonelloses

Related Publications

Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
September 2022, Journal for immunotherapy of cancer,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
November 2016, Proceedings of the National Academy of Sciences of the United States of America,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
November 2021, Cancer immunology research,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
July 2014, Journal of translational medicine,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
March 2023, Journal for immunotherapy of cancer,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
October 2012, ImmunoTargets and therapy,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
April 2015, Current opinion in immunology,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
August 2022, Journal of biomedical science,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
January 2017, Oncotarget,
Che-Hsin Lee, and Jeng-Long Hsieh, and Chao-Liang Wu, and Pei-Yu Hsu, and Ai-Li Shiau
January 2022, Oncoimmunology,
Copied contents to your clipboard!